Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Inhibition of HERG potassium channels by celecoxib and its mechanism Frolov RV; Ignatova II; Singh SPLoS One 2011[]; 6 (10): e26344BACKGROUND: Celecoxib (Celebrex), a widely prescribed selective inhibitor of cyclooxygenase-2, can modulate ion channels independently of cyclooxygenase inhibition. Clinically relevant concentrations of celecoxib can affect ionic currents and alter functioning of neurons and myocytes. In particular, inhibition of Kv2.1 channels by celecoxib leads to arrhythmic beating of Drosophila heart and of rat heart cells in culture. However, the spectrum of ion channels involved in human cardiac excitability differs from that in animal models, including mammalian models, making it difficult to evaluate the relevance of these observations to humans. Our aim was to examine the effects of celecoxib on hERG and other human channels critically involved in regulating human cardiac rhythm, and to explore the mechanisms of any observed effect on the hERG channels. METHODS AND RESULTS: Celecoxib inhibited the hERG, SCN5A, KCNQ1 and KCNQ1/MinK channels expressed in HEK-293 cells with IC(50)s of 6.0 microM, 7.5 microM, 3.5 microM and 3.7 microM respectively, and the KCND3/KChiP2 channels expressed in CHO cells with an IC(50) of 10.6 microM. Analysis of celecoxib's effects on hERG channels suggested gating modification as the mechanism of drug action. CONCLUSIONS: The above channels play a significant role in drug-induced long QT syndrome (LQTS) and short QT syndrome (SQTS). Regulatory guidelines require that all new drugs under development be tested for effects on the hERG channel prior to first administration in humans. Our observations raise the question of celecoxib's potential to induce cardiac arrhythmias or other channel related adverse effects, and make a case for examining such possibilities.|Animals[MESH]|Celecoxib[MESH]|Cell Line[MESH]|Cyclooxygenase 2 Inhibitors/*pharmacology[MESH]|Drosophila[MESH]|ERG1 Potassium Channel[MESH]|Ether-A-Go-Go Potassium Channels/*antagonists & inhibitors[MESH]|Humans[MESH]|Ion Channel Gating/drug effects[MESH]|Patch-Clamp Techniques[MESH]|Pyrazoles/*pharmacology[MESH]|Rats[MESH]|Sulfonamides/*pharmacology[MESH] |
